Tag: Neovasc

Neovasc Announces Second Quarter 2018 Financial Results

VANCOUVER, Aug. 8, 2018 /PRNewswire/ – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, today reported financial results for the second quarter ended June 30, […]

Neovasc Announces Collaboration and Licensing Agreement with Penn Medicine and the Gorman Cardiovascular Research Group

VANCOUVER, Aug. 3, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, announced today that it has entered into a collaboration and licensing agreement relating to certain know-how developed by Penn Medicine and the Gorman Cardiovascular Research […]

Neovasc Announces Filing of “Administrative” Prospectus Supplement Relating to Expiry of Prior Shelf Prospectus / Registration Statement

VANCOUVER, July 16, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that, in connection with its new final short form base shelf prospectus (the “Base Shelf Prospectus”) filed with securities regulatory authorities in the provinces of British Columbia, Alberta, Saskatchewan, Manitoba and Ontario (the “Provinces”) and its corresponding shelf registration statement on Form […]

Neovasc Receives Expected Delisting Determination from Nasdaq Staff and Will Request Nasdaq Hearing

VANCOUVER, July 9, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN) (TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will request a hearing before the Nasdaq Hearings Panel (the “Panel”) as the next step in the process to seeking an […]

Tiara and Reducer Featured at CSI Frankfurt 2018

VANCOUVER, July 2, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TZX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Tiara™ (“Tiara”), a transcatheter treatment of mitral valve disease, and the Neovasc Reducer™ (“Reducer”), a CE-Marked medical devices used for […]

Neovasc Announces Filing of Shelf Prospectus and Form F-10 Registration Statement

VANCOUVER, July 2, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that it has filed a preliminary short form base shelf prospectus with securities regulatory authorities in Canada, other than Quebec, and a corresponding shelf registration statement on Form F-10 (the “Registration Statement”) with the U.S. Securities and […]

Neovasc Announces First Implant of a Neovasc Reducer™ in a U.S. Patient

VANCOUVER, June 20, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced the first U.S. patient has been implanted with a Neovasc Reducer™ (the “Reducer”), a CE-Marked medical device for the treatment of refractory […]

Neovasc Announces Appointment of Steve Rubin as Chairman of the Board and General Update

VANCOUVER, June 11, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that its Board of Directors (the “Board”) has elected Steve Rubin as Chairman of the Board, effective immediately. Rubin succeeds Paul Geyer, who will remain a […]

Neovasc Inc. Reports Results of Annual General and Special Meeting of Shareholders

VANCOUVER, June 4, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General and Special Meeting of Shareholders held on June 4, 2018 in Vancouver, B.C. (the “Meeting”). At the Meeting, the shareholders of the Company (the “Shareholders”) re-elected […]

Neovasc Provides Highlights from EuroPCR; Symposium Generates Increased Interest in Reducer

VANCOUVER, May 25, 2018 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today provided highlights from EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions (EAPCI) of the European Society of Cardiology (ESC), which […]